FDA Approves Tucatinib as Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. This approval is supported by the phase 3 HER2CLIMB-05 trial, which showed that adding tucatinib extended median progression-free survival by 8.6 months.